Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update.

ABSTRACT:

Background

As the international community dealt with the ongoing COVID-19 pandemic, important progress continued to be made in the development of new drug-based therapies for the neurodegenerative condition of Parkinson's disease (PD) in 2021. This progress included both "symptomatic treatments" (ST - improves/reduces symptoms of the condition) and "disease modifying treatments" (DMT - attempts to delay/slow progression by addressing the underlying biology of PD), which can be categorised further based on their mechanisms of action and class of drug.

Objective

This report continues previous efforts to provide an overview of the pharmacological therapies - both ST and DMT - in clinical trials for PD during 2021- 2022, with the aim of creating greater awareness and involvement

SUBMITTER: McFarthing K 

PROVIDER: S-EPMC9198738 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature